can reduce various side effects of cancer chemotherapy and improve the treatment completion rate of cancer chemotherapy, which resulted in the completion of the present disclosure.

Accordingly, the present disclosure is as described below.

[0014]

In one aspect, the present disclosure refers to the use of an agent comprising (A) cystine and (B) theanine in combination in the manufacture of a medicament for improving the treatment completion rate of cancer chemotherapy, wherein said medicament is to be administered to a subject in need thereof. In another aspect, the present disclosure refers to the use of a combination of (A) cystine and (B) theanine in the manufacture of a medicament for use in reducing a side effect of cancer chemotherapy. In a further aspect, the present disclosure refers to the use of a combination of (A) cystine and (B) theanine in the manufacture of a medicament for use in improving the treatment completion rate of cancer chemotherapy.

[1] An agent for reducing side effects of cancer chemotherapy, comprising (A) cystine or a derivative thereof and (B) theanine in combination.

[2] The agent of the above-mentioned [1], which is a composition comprising (A) cystine or a derivative thereof and (B) theanine.

[3] The agent of the above-mentioned [1] or [2], wherein the weight ratio of (A) cystine or a derivative thereof and (B) theanine is A:B=100:1 - 1:100.

Claims

1. Use of an agent comprising (A) cystine and (B) theanine in combination in the manufacture of a medicament for improving the treatment completion rate of cancer chemotherapy, wherein said medicament is to be administered to a subject in need thereof.

2. The use according to claim 1, wherein said agent comprises: a composition comprising (A) cystine and (B) theanine.

3. The use according to claim 1 or 2, wherein said agent comprises: a first composition comprising (A) cystine; and a second composition comprising (B) theanine.

4. The use according to any one of claims 1 to 3, wherein said agent consists of (A) cystine and (B) theanine and at least one selected from the group consisting of binder, excipient, swelling agent, lubricant, flowability improver, gloss agent, sweetener, flavor, preservative, coating agent, carrier and stabilizer.

5. The use according to any one of claims 1 to 3, wherein said agent consists of (A) cystine and (B) theanine.

6. The use according to any one of claim 1 to 5, wherein the weight ratio of (A) cystine and (B) theanine is A:B=100:1 – 1:100.

7. The use according to any one of claims 1 to 6, wherein the weight ratio of (A) cystine and (B) theanine is A:B=20:1 – 1:2.

8. Use of a combination of (A) cystine and (B) theanine in the manufacture of a medicament for use in reducing a side effect of cancer chemotherapy.

9. Use of a combination of (A) cystine and (B) theanine in the manufacture of a medicament for use in improving the treatment completion rate of cancer chemotherapy.

10. The use according to any one of claims 1 to 9 wherein (A) is L-cystine.

11. The use according to any one of claims 1 to 10, wherein (B) is L-theanine.

12. The use according to any one of claims 1 to 11, wherein the side effect of cancer chemotherapy comprises a side effect that can lead to the suspension of cancer chemotherapy.

13. The use according to claim 12, wherein the side effect that can lead to the suspension of cancer chemotherapy is selected from the group consisting of anorexia, nausea, vomiting, diarrhea, stomatitis, malaise and granulocytopenia.